Global Biosimilar Monoclonal Antibodies Market By Type (Human Growth Hormones, Monoclonal Antibodies, Insulin, Peptides, Erythropoietin, And Others), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, And Others), By Region And Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2020-2029
- 133972
- 12-Dec
- PDF/PPT/Word
-
Report Details
The report on Biosimilar Monoclonal Antibodies Market offers in-depth analysis on market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report include the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global biosimilar monoclonal antibodies market is segmented on the basis of Type, Application, and geography. The worldwide market for Biosimilar Monoclonal Antibodies Market is expected to grow at a CAGR of roughly x.x% over the next ten years, and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.
Biosimilar Monoclonal Antibodies Market Scope:
By type, the market is segmented into Rituximab, Infliximab, Abciximab, Trastuzumab, Adalimumab, and Bevacizumab. By Application, the market is divided into Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, and Others.
Based on geography, market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Pfizer, Inc., Novartis AG, Reliance Life Sciences, Allergan plc, Coherus BioSciences, Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim GmbH, BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, BIOCAD, Genor BioPharma Co. Ltd, and Celltrion, Inc..
Key Market Segments
Type
Rituximab
Infliximab
Abciximab
Trastuzumab
Adalimumab
BevacizumabApplication
Oncology
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
OthersKey Market Players included in the report:
Pfizer, Inc.
Novartis AG
Reliance Life Sciences
Allergan plc
Coherus BioSciences, Inc.
Biocon
Dr. Reddy’s Laboratories Ltd.
Boehringer Ingelheim GmbH
BioXpress Therapeutics SA
Intas Pharmaceuticals Limited
BIOCAD
Genor BioPharma Co. Ltd
Celltrion, Inc.Reasons to Get this Report:
In an insight outlook, this research report has dedicated to several quantities of analysis industry research (global industry trends) and Biosimilar Monoclonal Antibodies Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Biosimilar Monoclonal Antibodies Market; high-growth regions; and market drivers, restraints, and also market chances.
The analysis covers Biosimilar Monoclonal Antibodies Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Biosimilar Monoclonal Antibodies Market across sections such as also Application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the Biosimilar Monoclonal Antibodies Market together side their company profiles, SWOT analysis, latest advancements, and business plans.The analysis objectives of the report are:
To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
To know the Biosimilar Monoclonal Antibodies Market by pinpointing its many subsegments.
To profile the important players and analyze their growth plans.
To endeavor the amount and value of Biosimilar Monoclonal Antibodies sub-markets, depending on key regions (various vital states).
To analyze Biosimilar Monoclonal Antibodies Market concerning growth trends, prospects, and also their participation in the entire sector.
To examine and study the Biosimilar Monoclonal Antibodies Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2012 to 2018, and also prediction to 2028.
Primary worldwide Biosimilar Monoclonal Antibodies Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market. -
Table Of Content
1. Biosimilar Monoclonal Antibodies Market Introduction
1.1. Definition
1.2. Taxonomy
1.3. Research Scope2. Executive Summary2.1. Key Findings by Major Segments
2.2. Top strategies by Major Players3. Global Biosimilar Monoclonal Antibodies Market Overview3.1. Biosimilar Monoclonal Antibodies Market Dynamics
3.1.1. Drivers
3.1.2. Opportunities
3.1.3. Restraints
3.1.4. Challenges3.2. PESTLE Analysis
3.3. Opportunity Map Analysis
3.4. PORTER’S Five Forces Analysis
3.5. Market Competition Scenario Analysis
3.6. Product Life Cycle Analysis
3.7. Opportunity Orbits
3.8. Manufacturer Intensity Map4. Global Biosimilar Monoclonal Antibodies Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-20284.1. Global Biosimilar Monoclonal Antibodies Market Analysis by Type: Introduction
4.2. Market Size and Forecast by Region
4.3. Rituximab
4.4. Infliximab
4.5. Abciximab
4.6. Trastuzumab
4.7. Adalimumab
4.8. Bevacizumab5. Global Biosimilar Monoclonal Antibodies Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-20285.1. Global Biosimilar Monoclonal Antibodies Market Analysis by Application: Introduction
5.2. Market Size and Forecast by Region
5.3. Oncology
5.4. Chronic and Autoimmune Diseases
5.5. Growth Hormone Deficiency
5.6. Infectious Diseases
5.7. Others6. Global Biosimilar Monoclonal Antibodies Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-20286.1. North America
6.1.1. North America Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
6.1.1.1. US
6.1.1.2. Canada
6.1.1.3. Mexico6.2.1. Europe
6.2.1. Europe Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
6.2.1.1. Germany
6.2.1.2. France
6.2.1.3. UK
6.2.1.4. Russia
6.2.1.5. Italy
6.2.1.6. Spain
6.2.1.7. Rest of Europe6.3. Asia-Pacific
6.3.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
6.3.1.1. China
6.3.1.2. Japan
6.3.1.3. Korea
6.3.1.4. India
6.3.1.5. Rest of Asia6.4. Latin America
6.4.1. Latin America Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
6.4.1.1. Brazil
6.4.1.2. Argentina
6.4.1.3. Rest of Latin America6.5. Middle East and Africa
6.5.1. Middle East and Africa Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
6.5.1.1. GCC
6.5.1.2. South Africa
6.5.1.3. Israel
6.5.1.4. Rest of MEA
7. Global Biosimilar Monoclonal Antibodies Market Competitive Landscape, Market Share Analysis, and Company Profiles7.1. Market Share Analysis
7.2. Company Profiles
7.3. Pfizer, Inc.7.3.1. Company Overview
7.3.2. Financial Highlights
7.3.3. Product Portfolio
7.3.4. SWOT Analysis
7.3.5. Key Strategies and Developments7.4. Novartis AG7.4.1. Company Overview
7.4.2. Financial Highlights
7.4.3. Product Portfolio
7.4.4. SWOT Analysis
7.4.5. Key Strategies and Developments7.5. Reliance Life Sciences7.5.1. Company Overview
7.5.2. Financial Highlights
7.5.3. Product Portfolio
7.5.4. SWOT Analysis
7.5.5. Key Strategies and Developments7.6. Allergan plc7.6.1. Company Overview
7.6.2. Financial Highlights
7.6.3. Product Portfolio
7.6.4. SWOT Analysis
7.6.5. Key Strategies and Developments7.7. Coherus BioSciences, Inc.7.7.1. Company Overview
7.7.2. Financial Highlights
7.7.3. Product Portfolio
7.7.4. SWOT Analysis
7.7.5. Key Strategies and Developments7.8. Biocon7.8.1. Company Overview
7.8.2. Financial Highlights
7.8.3. Product Portfolio
7.8.4. SWOT Analysis
7.8.5. Key Strategies and Developments7.9. Dr. Reddy’s Laboratories Ltd.7.9.1. Company Overview
7.9.2. Financial Highlights
7.9.3. Product Portfolio
7.9.4. SWOT Analysis
7.9.5. Key Strategies and Developments7.10. Boehringer Ingelheim GmbH7.10.1. Company Overview
7.10.2. Financial Highlights
7.10.3. Product Portfolio
7.10.4. SWOT Analysis
7.10.5. Key Strategies and Developments7.11. BioXpress Therapeutics SA7.11.1. Company Overview
7.11.2. Financial Highlights
7.11.3. Product Portfolio
7.11.4. SWOT Analysis
7.11.5. Key Strategies and Developments7.12. Intas Pharmaceuticals Limited7.12.1. Company Overview
7.12.2. Financial Highlights
7.12.3. Product Portfolio
7.12.4. SWOT Analysis
7.12.5. Key Strategies and Developments7.13. BIOCAD7.13.1. Company Overview
7.13.2. Financial Highlights
7.13.3. Product Portfolio
7.13.4. SWOT Analysis
7.13.5. Key Strategies and Developments7.14. Genor BioPharma Co. Ltd7.14.1. Company Overview
7.14.2. Financial Highlights
7.14.3. Product Portfolio
7.14.4. SWOT Analysis
7.14.5. Key Strategies and Developments7.15. Celltrion, Inc.7.15.1. Company Overview
7.15.2. Financial Highlights
7.15.3. Product Portfolio
7.15.4. SWOT Analysis
7.15.5. Key Strategies and Developments8. Assumptions and Acronyms
9. Research Methodology
10. Contact -
Inquiry Before Buying
-
Request Sample
